Passa al contenuto
Merck
Tutte le immagini(3)

Documenti fondamentali

Visualizza tutta la documentazione

SML0223

Sigma-Aldrich

Zoledronic acid monohydrate

≥98% (HPLC)

Sinonimo/i:

P,P′-[1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene]bisphosphonic acid monohydrate, Zoledronate monohydrate, [1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid) monohydrate

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(3)

About This Item

Formula empirica (notazione di Hill):
C5H10N2O7P2·H2O
Numero CAS:
165800-06-6
Peso molecolare:
290.10
Numero MDL:
MFCD08448695
Codice UNSPSC:
12352204
ID PubChem:
329825242
NACRES:
NA.77

Livello qualitativo

100

Saggio

≥98% (HPLC)

Stato

powder

Condizioni di stoccaggio

desiccated
protect from light

Colore

white to beige

Solubilità

H2O: ≥2 mg/mL

Temperatura di conservazione

2-8°C

Stringa SMILE

O.OC(Cn1ccnc1)(P(O)(O)=O)P(O)(O)=O

InChI

1S/C5H10N2O7P2.H2O/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7;/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14);1H2
FUXFIVRTGHOMSO-UHFFFAOYSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Applicazioni

Zoledronic acid monohydrate has been used:
  • as an inhibitor for cell proliferation in glioblastoma, breast cancer tumor and prostate cancer cell line LAPC4
  • as a conjugate with D,L-lactide 75: glycolide 25 (PLGA) to analyze its bone formation functionality in distal femur
  • as an inhibitor for farnesyl diphosphate synthase enzyme in glioblastoma cells

Azioni biochim/fisiol

Zoledronic acid (zoledronate) is a bisphosphonate bone resorption inhibitor, an inhibitor of farnesyl diphosphate (FPP) synthase which results in downstream inhibition of osteoclast activity and reduced bone resorption and turnover. It has been used to treat postmenopausal osteoporosis, Paget′s disease, hypercalcemia, and along with cancer chemotherapy to treat bone damage caused by cancer that has spread to the bones.

Nota sulla preparazione

This product is extremely unstable in solution and should be used shortly after reconstitution. If storage of the solution is necessary it can be held at 2-8ºC for no more than 24 hours.

Pittogrammi

Exclamation mark
GHS07

Avvertenze

Warning

Indicazioni di pericolo

H315,H319,H335

Classi di pericolo

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Organi bersaglio

Respiratory system

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
045M4706V
035M4786V
064M4703V
103M4742V
122M4719V

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Xu Li et al.
International journal of pharmaceutics, 526(1-2), 69-76 (2017-04-30)
Bisphosphonates are used to treat bone diseases such as osteoporosis and cancer-induced bone pain and fractures. It is thought that modifying the pharmacokinetics and biodistribution profiles of bisphosphonates (i.e. rapid renal clearance and extensive bone absorption) will not only reduce
Xu Li et al.
ACS applied materials & interfaces, 11(7), 7311-7319 (2019-01-29)
Bisphosphonates are generally used to treat bone diseases, such as bone metastasis from cancer. There is evidence that, through the modification of the pharmacokinetics and biodistribution of bisphosphonates by formulating them into nanoparticles, they may be able to treat extraskeletal
Kiichi Yamamoto et al.
Parasitology international, 66(2), 89-99 (2016-12-07)
Recent evidence suggests that 1α,25-dihydroxyvitamin D3 (calcitriol, VD3), the active form of vitamin D (VD), can inhibit the proliferation of microorganisms. In the present study, we conducted in vitro experiments and utilized in vivo murine models to investigate the antimalarial
Low-dose zoledronate for the treatment of bone metastasis secondary to prostate cancer
Akoury E, et al.
Cancer Cell International, 19(1), 28-28 (2019)
Controlled delivery of zoledronate improved bone formation locally in vivo
Gou W, et al.
PLoS ONE, 9(3), e91317-e91317 (2014)
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.